Science 37 (SNCE) Scheduled to Post Quarterly Earnings on Monday

Posted by Defense World Staff on May 8th, 2023

Science 37 (NASDAQ:SNCE – Get Rating) is set to issue its quarterly earnings data before the market opens on Monday, May 15th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter. Science 37 has set its FY 2023 guidance at EPS.Parties that wish to register for the company’s conference call can do so using this link.

Science 37 (NASDAQ:SNCE – Get Rating) last announced its quarterly earnings results on Monday, March 6th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.02. The firm had revenue of $15.94 million for the quarter, compared to analysts’ expectations of $14.46 million. Science 37 had a negative return on equity of 69.42% and a negative net margin of 72.69%.

Science 37 Price Performance

Science 37 stock opened at $0.28 on Monday. The business’s fifty day moving average is $0.30 and its two-hundred day moving average is $0.54. Science 37 has a 52 week low of $0.19 and a 52 week high of $4.31.

Hedge Funds Weigh In On Science 37

Several large investors have recently made changes to their positions in SNCE. State Street Corp lifted its stake in shares of Science 37 by 442.0% during the second quarter. State Street Corp now owns 946,713 shares of the company’s stock valued at $1,903,000 after acquiring an additional 772,035 shares during the period. Northern Trust Corp lifted its stake in shares of Science 37 by 470.8% during the second quarter. Northern Trust Corp now owns 508,353 shares of the company’s stock valued at $1,022,000 after acquiring an additional 419,290 shares during the period. Alyeska Investment Group L.P. lifted its stake in shares of Science 37 by 39.8% during the fourth quarter. Alyeska Investment Group L.P. now owns 1,466,384 shares of the company’s stock valued at $609,000 after acquiring an additional 417,378 shares during the period. Citadel Advisors LLC lifted its stake in shares of Science 37 by 24.7% during the second quarter. Citadel Advisors LLC now owns 1,781,312 shares of the company’s stock valued at $3,581,000 after acquiring an additional 353,156 shares during the period. Finally, Walleye Capital LLC lifted its stake in shares of Science 37 by 2,261.0% during the first quarter. Walleye Capital LLC now owns 309,956 shares of the company’s stock valued at $1,658,000 after acquiring an additional 296,828 shares during the period. Institutional investors and hedge funds own 50.85% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Robert W. Baird reduced their price objective on Science 37 from $2.00 to $1.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 7th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $3.50.

Science 37 Company Profile

(Get Rating)

Science 37 Holdings, Inc provides technology-based solutions to enable agile clinical trials and decentralized approaches. Its platform enables modern and digital approaches to clinical research by bringing together all parties, including the patient and trial investigators, nurses, coordinators, and sponsors to power workflows, centralize evidence generation, and harmonize data.